413 related articles for article (PubMed ID: 23350198)
21. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
Ruckova E; Muller P; Nenutil R; Vojtesek B
Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
[TBL] [Abstract][Full Text] [Related]
22. [Changes in heat shock protein synthesis and thermotolerance of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 by geldanamycin].
Kozeko LG
Tsitologiia; 2014; 56(6):419-26. PubMed ID: 25696978
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of heat shock protein 90 augment endothelin‑1‑induced heat shock protein 27 through the SAPK/JNK signaling pathway in osteoblasts.
Fujita K; Otsuka T; Kawabata T; Sakai G; Matsushima-Nishiwaki R; Kozawa O; Tokuda H
Mol Med Rep; 2018 Jun; 17(6):8542-8547. PubMed ID: 29658585
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
[TBL] [Abstract][Full Text] [Related]
25. A novel C-terminal homologue of Aha1 co-chaperone binds to heat shock protein 90 and stimulates its ATPase activity in Entamoeba histolytica.
Singh M; Shah V; Tatu U
J Mol Biol; 2014 Apr; 426(8):1786-98. PubMed ID: 24486610
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
Shen G; Wang M; Welch TR; Blagg BS
J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
[TBL] [Abstract][Full Text] [Related]
27. Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses.
Tukaj S; Tiburzy B; Manz R; de Castro Marques A; Orosz A; Ludwig RJ; Zillikens D; Kasperkiewicz M
Exp Dermatol; 2014 Aug; 23(8):585-90. PubMed ID: 24961936
[TBL] [Abstract][Full Text] [Related]
28. Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.
Brychzy A; Rein T; Winklhofer KF; Hartl FU; Young JC; Obermann WM
EMBO J; 2003 Jul; 22(14):3613-23. PubMed ID: 12853476
[TBL] [Abstract][Full Text] [Related]
29. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.
Powers MV; Clarke PA; Workman P
Cancer Cell; 2008 Sep; 14(3):250-62. PubMed ID: 18772114
[TBL] [Abstract][Full Text] [Related]
30. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
[TBL] [Abstract][Full Text] [Related]
31. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
Kimura T; Uesugi M; Takase K; Miyamoto N; Sawada K
Toxicol Appl Pharmacol; 2017 Aug; 329():282-292. PubMed ID: 28624441
[TBL] [Abstract][Full Text] [Related]
32. Both the N- and C-terminal chaperone sites of Hsp90 participate in protein refolding.
Minami M; Nakamura M; Emori Y; Minami Y
Eur J Biochem; 2001 Apr; 268(8):2520-4. PubMed ID: 11298772
[TBL] [Abstract][Full Text] [Related]
33. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
34. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Maloney A; Clarke PA; Naaby-Hansen S; Stein R; Koopman JO; Akpan A; Yang A; Zvelebil M; Cramer R; Stimson L; Aherne W; Banerji U; Judson I; Sharp S; Powers M; deBilly E; Salmons J; Walton M; Burlingame A; Waterfield M; Workman P
Cancer Res; 2007 Apr; 67(7):3239-53. PubMed ID: 17409432
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein antagonists in early stage clinical trials for NSCLC.
Hendriks LEL; Dingemans AC
Expert Opin Investig Drugs; 2017 May; 26(5):541-550. PubMed ID: 28274158
[TBL] [Abstract][Full Text] [Related]
36. Induction of heat shock protein HSPA6 (HSP70B') upon HSP90 inhibition in cancer cell lines.
Kuballa P; Baumann AL; Mayer K; Bär U; Burtscher H; Brinkmann U
FEBS Lett; 2015 Jun; 589(13):1450-8. PubMed ID: 25957766
[TBL] [Abstract][Full Text] [Related]
37. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Reikvam H; Nepstad I; Sulen A; Gjertsen BT; Hatfield KJ; Bruserud Ø
Expert Opin Investig Drugs; 2013 May; 22(5):551-63. PubMed ID: 23586877
[TBL] [Abstract][Full Text] [Related]
38. RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.
Alfano L; Guida T; Provitera L; Vecchio G; Billaud M; Santoro M; Carlomagno F
J Clin Endocrinol Metab; 2010 Jul; 95(7):3552-7. PubMed ID: 20444924
[TBL] [Abstract][Full Text] [Related]
39. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.
Ficker E; Dennis AT; Wang L; Brown AM
Circ Res; 2003 Jun; 92(12):e87-100. PubMed ID: 12775586
[TBL] [Abstract][Full Text] [Related]
40. Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.
Myung SJ; Yoon JH; Kim BH; Lee JH; Jung EU; Lee HS
J Pharmacol Exp Ther; 2009 Jul; 330(1):276-82. PubMed ID: 19329756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
